Drugs / ARGX-213
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06968338 | Apr 2025 → Mar 2026 | — | argenx | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARGX-213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06968338 ↗ |
| Route | Intravenous | “Intravenous or subcutaneous administrations of ARGX-213” NCT06968338 ↗ |
| Route | Subcutaneous | “Intravenous or subcutaneous administrations of ARGX-213” NCT06968338 ↗ |